Literature DB >> 33846559

Improved transplant outcomes with myeloablative conditioning for hemophagocytic lymphohistiocytosis in HLA-matched and mismatched donors: a national multicenter retrospective study.

Yarden Greental Ness1, Amir A Kuperman1,2, Jerry Stein3,4, Joanne Yacobovich3,4, Ehud Even-Or5, Irina Zaidman5, Aharon Gefen6, Neta Nevo6, Bernice Oberman7, Amos Toren4,8, Polina Stepensky5, Bella Bielorai4,8, Elad Jacoby9,10.   

Abstract

We report the results of national retrospective study of 45 children with hemophagocytic lymphohistiocytosis (HLH) who underwent allogeneic hematopoietic stem-cell transplantation (HSCT) in Israel between the years 2000-2018. Donors were either HLA-matched (n = 26), partially mismatched (n = 7), haploidentical (n = 8), or cord-blood (n = 4). Myeloablative conditioning (MAC) was used in 20 procedures, and reduced-intensity conditioning (RIC) in 25. Forty-two patients engrafted, two had primary graft failure (one successfully retransplanted), one died prior to engraftment, and two developed secondary graft failure. Of the eight patients who had mixed donor chimerism at day 30 (5-95%), five achieved stable mixed or full donor chimerism. The 5-year probabilities of overall survival and event-free survival (EFS) were 86% and 82%, respectively. Five-year EFS was lower for patients receiving RIC compared to MAC (72% vs. 100%, p = 0.018) and following alternative-donor transplant (68% vs. 92% for HLA-matched donors, p = 0.034), mostly due to increased transplant-related mortality (TRM). Thus, both HLA-matched and alternative donor transplant procedures may benefit form a myeloablative conditioning regimen.

Entities:  

Year:  2021        PMID: 33846559     DOI: 10.1038/s41409-021-01290-1

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  40 in total

1.  Munc18-2 deficiency causes familial hemophagocytic lymphohistiocytosis type 5 and impairs cytotoxic granule exocytosis in patient NK cells.

Authors:  Marjorie Côte; Mickaël M Ménager; Agathe Burgess; Nizar Mahlaoui; Capucine Picard; Catherine Schaffner; Fahad Al-Manjomi; Musa Al-Harbi; Abdullah Alangari; Françoise Le Deist; Andrew R Gennery; Nathalie Prince; Astrid Cariou; Patrick Nitschke; Ulrich Blank; Gehad El-Ghazali; Gaël Ménasché; Sylvain Latour; Alain Fischer; Geneviève de Saint Basile
Journal:  J Clin Invest       Date:  2009-11-02       Impact factor: 14.808

Review 2.  Molecular and cellular pathogenesis of X-linked lymphoproliferative disease.

Authors:  Kim E Nichols; Cindy S Ma; Jennifer L Cannons; Pamela L Schwartzberg; Stuart G Tangye
Journal:  Immunol Rev       Date:  2005-02       Impact factor: 12.988

Review 3.  How I treat hemophagocytic lymphohistiocytosis.

Authors:  Michael B Jordan; Carl E Allen; Sheila Weitzman; Alexandra H Filipovich; Kenneth L McClain
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

4.  A multicenter study of patients with multisystem Langerhans cell histiocytosis who develop secondary hemophagocytic lymphohistiocytosis.

Authors:  Deepak Chellapandian; Melissa R Hines; Rui Zhang; Michael Jeng; Cor van den Bos; Vicente Santa-María López; Kai Lehmberg; Elena Sieni; Yini Wang; Taizo Nakano; James A Williams; Nicholas J Fustino; Itziar Astigarraga; Ira J Dunkel; Oussama Abla; Astrid G S van Halteren; Deqing Pei; Cheng Cheng; Sheila Weitzman; Lillian Sung; Kim E Nichols
Journal:  Cancer       Date:  2018-12-06       Impact factor: 6.860

5.  Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study.

Authors:  Elisabet Bergsten; AnnaCarin Horne; Maurizio Aricó; Itziar Astigarraga; R Maarten Egeler; Alexandra H Filipovich; Eiichi Ishii; Gritta Janka; Stephan Ladisch; Kai Lehmberg; Kenneth L McClain; Milen Minkov; Scott Montgomery; Vasanta Nanduri; Diego Rosso; Jan-Inge Henter
Journal:  Blood       Date:  2017-09-21       Impact factor: 22.113

6.  Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11.

Authors:  Udo zur Stadt; Susanne Schmidt; Brigitte Kasper; Karin Beutel; A Sarper Diler; Jan-Inge Henter; Hartmut Kabisch; Reinhard Schneppenheim; Peter Nürnberg; Gritta Janka; Hans Christian Hennies
Journal:  Hum Mol Genet       Date:  2005-02-09       Impact factor: 6.150

7.  Spectrum of perforin gene mutations in familial hemophagocytic lymphohistiocytosis.

Authors:  K Göransdotter Ericson; B Fadeel; S Nilsson-Ardnor; C Söderhäll; A Samuelsson; G Janka; M Schneider; A Gürgey; N Yalman; T Révész; R Egeler; K Jahnukainen; I Storm-Mathiesen; A Haraldsson ; J Poole; G de Saint Basile; M Nordenskjöld; J Henter
Journal:  Am J Hum Genet       Date:  2001-02-06       Impact factor: 11.025

8.  Treatment of the X-linked lymphoproliferative, Griscelli and Chédiak-Higashi syndromes by HLH directed therapy.

Authors:  Helena Trottestam; Karin Beutel; Marie Meeths; Niels Carlsen; Carsten Heilmann; Srdjan Pasić; David Webb; Henrik Hasle; Jan-Inge Henter
Journal:  Pediatr Blood Cancer       Date:  2009-02       Impact factor: 3.167

9.  Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3).

Authors:  Jérôme Feldmann; Isabelle Callebaut; Graça Raposo; Stéphanie Certain; Delphine Bacq; Cécile Dumont; Nathalie Lambert; Marie Ouachée-Chardin; Gaëlle Chedeville; Hannah Tamary; Véronique Minard-Colin; Etienne Vilmer; Stéphane Blanche; Françoise Le Deist; Alain Fischer; Geneviève de Saint Basile
Journal:  Cell       Date:  2003-11-14       Impact factor: 41.582

10.  Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis.

Authors:  Ivan K Chinn; Olive S Eckstein; Erin C Peckham-Gregory; Baruch R Goldberg; Lisa R Forbes; Sarah K Nicholas; Emily M Mace; Tiphanie P Vogel; Harshal A Abhyankar; Maria I Diaz; Helen E Heslop; Robert A Krance; Caridad A Martinez; Trung C Nguyen; Dalia A Bashir; Jordana R Goldman; Asbjørg Stray-Pedersen; Luis A Pedroza; M Cecilia Poli; Juan C Aldave-Becerra; Sean A McGhee; Waleed Al-Herz; Aghiad Chamdin; Zeynep H Coban-Akdemir; Shalini N Jhangiani; Donna M Muzny; Tram N Cao; Diana N Hong; Richard A Gibbs; James R Lupski; Jordan S Orange; Kenneth L McClain; Carl E Allen
Journal:  Blood       Date:  2018-04-09       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.